Published small studies show some participants achieving stabilised or slightly improved bone density, but 'success' definitions vary widely—some use any halt to density loss, others require measurable gain. Across trials, roughly 40–60% of treated participants showed some positive marker response, though fracture-risk reduction has not been formally demonstrated in controlled settings.
A review of registered clinical trials identified 14 completed or published studies in osteoporosis using cell-based approaches, predominantly with placental MSCs, alongside 2 currently recruiting trials. Trial sizes have ranged from 20 to 120 participants. Several small studies report modest improvements in bone mineral density (typically 3–8% change from baseline over 12–24 months) and some reduction in fracture markers, though methodological heterogeneity limits direct comparison. No large, multi-centre, phase III efficacy trial has yet reported.
Sunt un candidat? → · Osteoporosis & Bone Health: full overview → · Cost Osteoporoza și Sănătatea Oaselor → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită